007足球比分即时网

Bio-Thera Solutions’ Golimumab Biosimilars Receive FDA Approval as First Biosimilars to Simponi® and Simponi Aria®; Accord BioPharma to Commercialize IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi) in the United States

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

05-272025

Bio-Thera Solutions and Hikma Pharmaceuticals Announce FDA Approval of STARJEMZA® (ustekinumab-hmny) Injection, a biosimilar referencing STELARA® (ustekinumab) Injection

Guangzhou and London – May 22, 2025) Injection, a biosimilarreferencing Stelara® (ustekinumab) Injection. STARJEMZA® is ...
04-142025

Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Guangzhou, China– April 14, 2025 –Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical companydeve...
03-262025

Bio-Thera and Dr. Reddy’s Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Guangzhou, China/ Hyderabad, India – March 26,2025 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-stagebio...

上一页 ···6 7 8 9 10 ··· 下一页